In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price target of $8.00. The company’s shares closed last Friday at $4.68.
Renza covers the Healthcare sector, focusing on stocks such as Amgen, Exelixis, and IDEAYA Biosciences. According to TipRanks, Renza has an average return of 17.7% and a 48.75% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADC Therapeutics with a $7.67 average price target, which is a 63.89% upside from current levels. In a report released on February 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
See the top stocks recommended by analysts >>
ADCT market cap is currently $377.4M and has a P/E ratio of -2.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADC Therapeutics (ADCT) Company Description:
ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company’s product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.
Read More on ADCT:
